Updates on the role of adrenal steroidogenesis inhibitors in Cushing’s syndrome: a focus on novel therapies

@inproceedings{Fleseriu2016UpdatesOT,
  title={Updates on the role of adrenal steroidogenesis inhibitors in Cushing’s syndrome: a focus on novel therapies},
  author={Maria Fleseriu and Fr{\'e}d{\'e}ric Castinetti},
  booktitle={Pituitary},
  year={2016}
}
Endogenous Cushing’s syndrome (CS) is a rare disease that results from exposure to high levels of cortisol; Cushing’s disease (CD) is the most frequent form of CS. Patients with CS suffer from a variety of comorbidities that increase the risk of mortality. Surgical resection of the disease-causing lesion is generally the first-line treatment of CS. However, some patients may not be eligible for surgery due to comorbidities, and approximately 25 % of patients, especially those with CD, have… CONTINUE READING
4 Citations
68 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 68 references

Pharmacology of COR-003 (levoketoconazole), an investigational treatment for endogenous Cushing’s syndrome

  • R Thieroff-Ekerdt, P Lavin, M Abou-Gharbia, N France
  • 2016
Highly Influential
6 Excerpts

Effects of osilodrostat (LCI699) on cytochrome P450 enzymes in healthy volunteers indicates a low drug-drug interactions potential

  • L Ting, AP Tripahti, C Darstein, T White, N Sauter
  • Endocrine Abstracts 37,
  • 2015
Highly Influential
5 Excerpts

Similar Papers

Loading similar papers…